Peptides that inhibit binding of EPCR to its ligand to treat inflammation
AssigneeTel HaShomer Medical Research Infrastructure and Services Ltd.
InventorsNicola Maggio, Joab Chapman, Efrat Shavit Stein
Life of this patent
Estimating the term…
Abstract
An isolated peptide of up to 6 amino acids comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR is disclosed. Also disclosed is an isolated peptide comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR, wherein the peptide comprises a modification in at least one amino acid. Also disclosed is a molecule comprising an amino acid sequence which inhibits binding of an endothelial cell protein C receptor (EPCR) ligand to the EPCR attached to a heterologous moiety. Pharmaceutical compositions and methods of treatment are also disclosed.
Claims4
A pharmaceutical composition comprising, as the active ingredient, an isolated peptide consisting of the amino acid sequence of SEQ ID NO:
- 6, wherein the N-terminal glutamic acid is γ-carboxy glutamine {Gla}, wherein the N-terminal glutamic acid is tosylated, and having a C-terminal amide modification, and a pharmaceutically acceptable carrier, wherein said pharmaceutical composition is non-immunogenic.
Dependencies are inferred from the claim text.